Accelerating Pace of Approvals and a Strong Development Pipeline Indicate Vigorous Growth for New Biotech Products, According to ...
BOSTON, MA--(Marketwired - May 9, 2017) - Biopharmaceuticals accounted for 35% of all new drug approvals in the United States from 2006 through 2016, and a robust development pipeline suggests that the recent increased pace of biotech approvals will …